Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Novoste Corporation (NasdaqNM:NOVT)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
3890 Steve Reynolds Blvd.
Norcross, GA 30093
Phone: (770) 717-0904
Fax: (770) 717-1106
Email: cjohnson@novoste.com
Employees (last reported count): 236
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Medical Equipment & Supplies
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 46%
·Over the last 6 months:
 · 3 insider buys; 10.0K shares (0.1% of insider shares)
 · 5 insider sells; 54.0K shares
  (0.7% of insider shares)
·Institutional: 95% (175% of float)
(224 institutions)
·Net Inst. Buying: 1.69M shares (+9.89%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Novoste Corporation has developed the Beta-Cath System, a hand-held device to deliver beta, or low penetration, radiation to the site of a treated blockage in a coronary artery to decrease the likelihood of restenosis. Restenosis, the renarrowing of a previously treated artery, is the major limitation of percutaneous coronary intervention (PTCA), a procedure used by interventional cardiologists to open blocked coronary arteries. The Beta-Cath System has been shown to reduce the incidence of restenosis in-patients who are being treated for blocked stents, or in-stent restenosis. The Beta-Cath System is designed to fit well with techniques currently used by interventional cardiologists in the cath lab. It is a hand-held device that hydraulically delivers beta radiation sources through a closed-end catheter to the area of the coronary artery injured by the immediately preceding PTCA procedure.
More from Market Guide: Expanded Business Description

Financial Summary
NOVT is a medical device company engaged in commercializing the Beta-Cath System, an intraluminal beta radiation catheter delivery system designed to reduce restenosis. For the six months ended 6/30/01, revenues totaled $26.6 million, up from $2 million. Net loss fell 31% to $9.9 million. Revenues reflect the sale of the Beta-Cath (TM) System in the U.S. Net loss was partially offset higher support personnel, trade show and consulting expenses.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Thomas Weldon, 45
Chairman
--  --  
William Hawkins, 47
Pres, CEO, Director
$423K$808K
Edwin Cordell, Jr., 42
CFO
--  --  
Daniel Hall, 53
VP, Gen. Counsel
--  --  
Robert Wood, Jr., 46
VP of Sales
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NOVTAs of 31-Aug-2001
Price and Volume
52-Week Low
on 19-Mar-2001
$13.00 
Recent Price$18.25 
52-Week High
on 7-Sep-2000
$57.00 
Beta1.19 
Daily Volume (3-month avg)435.9K
Daily Volume (10-day avg)785.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-66.1%
52-Week Change
relative to S&P500
-54.5%
Share-Related Items
Market Capitalization$295.7M
Shares Outstanding16.2M
Float8.80M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$3.56 
Earnings (ttm)-$1.79 
Earnings (mrq)-$0.20 
Sales (ttm)$1.94 
Cash (mrq)$2.26 
Valuation Ratios
Price/Book (mrq)5.12 
Price/EarningsN/A 
Price/Sales (ttm)9.42 
Income Statements
Sales (ttm)$31.1M
EBITDA (ttm)-$28.2M
Income available to common (ttm)-$28.7M
Profitability
Profit Margin (ttm)-92.3%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-36.27%
Return on Equity (ttm)-41.52%
Financial Strength
Current Ratio (mrq)3.79 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$36.6M
Short Interest
As of 8-Aug-2001
Shares Short2.89M
Percent of Float32.9%
Shares Short
(Prior Month)
2.79M
Short Ratio5.96 
Daily Volume486.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.